| Identification | Back Directory | [Name]
Lu AA47070 | [CAS]
913842-25-8 | [Synonyms]
Lu AA47070
Lu AA 47070 (90% Purity)
MSWIQSFUBYCFJE-PGMHBOJBSA-N
4-[(3,3-Dimethyl-1-oxobutyl)amino]-3,5-difluoro-N-[3-[(phosphonooxy)methyl]-2(3H)-thiazolylidene]benzamide
Benzamide, 4-[(3,3-dimethyl-1-oxobutyl)amino]-3,5-difluoro-N-[3-[(phosphonooxy)methyl]-2(3H)-thiazolylidene]- | [Molecular Formula]
C17H20F2N3O6PS | [MDL Number]
MFCD18782735 | [MOL File]
913842-25-8.mol | [Molecular Weight]
463.39 |
| Chemical Properties | Back Directory | [density ]
1.516±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly) | [form ]
Solid | [pka]
1.592±0.10(predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Uses]
Lu AA 47070 (90% Purity) is a novel adenosine A2A antagonist and can also reverse the effects of D2 receptor blockade, which is associated with parkinsonism. Lu AA 47070 has potential therapeutic use towards the treatment of Parkinson’s Disease. | [in vivo]
Lu AA47070 (3.75, 7.5, 15, 30 mg/kg; i.p.) reverseS the tremulous jaw movements, catalepsy, and locomotor suppression induced by subchronic administration of the D2 antagonist pimozide (1.0 mg/kg IP)[2].
Pharmacokinetic Parameters of Lu AA47070 in Sprague-Dawley rats[1].
| Compd | dose （mg/kg） | AUC(ng*h/L) | Tmax (h) | Cmax (ng/mL) | F (%) | | 32 | 1.5 | 2.9±0.7 | 0.5±0.1 | 869±68 | 55±13 | | 32 | 15 | 35±3.0 | 0.4±0.2 | 6413±281 | 66±6 |
Sprague-Dawley rats, 1.5, 15 mg/kg po [1]| Animal Model: | Male Sprague Dawley rats[2] | | Dosage: | 3.75, 7.5, 15, 30 mg/kg | | Administration: | I.p. | | Result: | Reversed the tremulous jaw movements, catalepsy, and locomotor suppression induced by subchronic administration of the D2 antagonist pimozide (1.0 mg/kg IP). |
|
|
|